KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

NCT04237649 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Solid Tumors

Interventions

DRUG: KAZ954
DRUG: PDR001
DRUG: NIR178
DRUG: NZV930

Sponsor

Novartis Pharmaceuticals